| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Modified Organism
Proteqflu - equine influenza vaccine
Record information and status
Record ID
Date of creation
2011-03-16 02:07 UTC (geoff.ridley@epa.govt.nz)
Date of last update
2014-05-18 19:48 UTC (kirsty.allen@epa.govt.nz)
Date of publication
2014-05-19 14:31 UTC (dina.abdelhakim@cbd.int)

Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.

LMO name
Proteqflu - equine influenza vaccine
Transformation event
Strains vCP2242 and vCP1533
Phone:+33 472 72 3000
"Proteqflu" is a vaccine made from recombinant canary pox virus modified with haemagglutinin gene from Equine Influenza. This LMO is used to vaccinate horses against Equine Influenza.

After inoculation, the viruses do not multiply in the horse but express the protective proteins. As a consequence, these components induce immunity against equine influenza virus (H3N8).
Recipient Organism or Parental Organisms
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Canarypox virus - CNPV
Related LMOs
Proteqflu-Te - equine influenza vaccine
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Characteristics of the transformation process
Techniques used for the modification
  • Homologous Recombination
Genetic elements construct
C5 right flanking arm
0.00 Kb
H6 Gene Promoter
0.00 Kb
Hemagglutinin gene
0.00 Kb
C5 left flanking arm
0.00 Kb
Further details
Notes regarding the genetic elements introduced or modified in this LMO
The following strains of Influenza viruses were used as donor organisms:

Influenza A/equine-2/Ohio/03[H3N8]Canarypox virus (vCP2242 - American strain)and Influenza A/equi-2/Newmarket/2/93 [H3N8] recombinant Canarypox virus (vCP1533 - European strain).
LMO characteristics
Modified traits
  • Use as vaccine
Common use(s)
  • Vaccine

Records referencing this document (4)
4record(s) found
Country's Decision or any other Communication2 records
Modified Organism1 record
Risk Assessment1 record